9 July 2018 - The MS Trust is very disappointed that the Scottish Medicines Consortium is unable to recommend ocrelizumab as an NHS treatment for relapsing remitting MS in Scotland.

The SMC say that they do not consider ocrelizumab to be cost effective for the NHS in Scotland (link is external) as a treatment for relapsing remitting MS in comparison to the existing disease modifying drugs. The SMC state that Roche, the manufacturer of the drug, did not present a sufficiently robust economic assessment of the drug's use for it to be accepted.

We anticipate that Roche will continue to work with the SMC with the aim of changing this initial decision.

We also understand that the SMC submission for ocrelizumab for primary progressive MS has been withdrawn.

Read Multiple Sclerosis Trust press release